131 related articles for article (PubMed ID: 32303129)
21. The association between NQO1 Pro187Ser polymorphism and bladder cancer susceptibility: a meta-analysis of 15 studies.
Yang S; Jin T; Su HX; Zhu JH; Wang DW; Zhu SJ; Li S; He J; Chen YH
PLoS One; 2015; 10(1):e0116500. PubMed ID: 25602258
[TBL] [Abstract][Full Text] [Related]
22. Association between NQO1 C609T polymorphism and colorectal cancer risk.
Wang Y; Zhang G; Luo Y
Tumour Biol; 2013 Dec; 34(6):4027-32. PubMed ID: 23893397
[TBL] [Abstract][Full Text] [Related]
23. The NQO1 C609T polymorphism and hepatocellular carcinoma risk.
Fan Y; Hu D; Feng B; Wang W
Tumour Biol; 2014 Aug; 35(8):7343-50. PubMed ID: 24532470
[TBL] [Abstract][Full Text] [Related]
24. Association of bladder cancer risk with an NAD(P)H:quinone oxidoreductase polymorphism in an ethnic Kashmiri population.
Pandith AA; Khan NP; Shah ZA; Shah AM; Wani SM; Siddiqi MA
Biochem Genet; 2011 Aug; 49(7-8):417-26. PubMed ID: 21253823
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphism 609C>T in NAD(P)H:quinone oxidoreductase 1 enhances the risk of proximal colon cancer.
Freriksen JJ; Salomon J; Roelofs HM; Te Morsche RH; van der Stappen JW; Dura P; Witteman BJ; Lacko M; Peters WH
J Hum Genet; 2014 Jul; 59(7):381-6. PubMed ID: 24830960
[TBL] [Abstract][Full Text] [Related]
26. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a meta-analysis.
Lou Y; Li R; Xiong L; Gu A; Shi C; Chu T; Zhang X; Gu P; Zhong H; Wen S; Han B
Tumour Biol; 2013 Dec; 34(6):3967-79. PubMed ID: 23852860
[TBL] [Abstract][Full Text] [Related]
27. NAD(P)H quinone oxidoreductase 1 (NQO1) genetic C609T polymorphism is associated with the risk of digestive tract cancer: a meta-analysis based on 21 case-control studies.
Yang FY; Guan QK; Cui YH; Zhao ZQ; Rao W; Xi Z
Eur J Cancer Prev; 2012 Sep; 21(5):432-41. PubMed ID: 22387672
[TBL] [Abstract][Full Text] [Related]
28. Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India.
Mandal RK; Nissar K; Mittal RD
Mol Biol Rep; 2012 Dec; 39(12):11145-52. PubMed ID: 23054000
[TBL] [Abstract][Full Text] [Related]
29. An association between NQO1 genetic polymorphism and risk of bladder cancer.
Park SJ; Zhao H; Spitz MR; Grossman HB; Wu X
Mutat Res; 2003 Apr; 536(1-2):131-7. PubMed ID: 12694753
[TBL] [Abstract][Full Text] [Related]
30. The rs1050450 C > T polymorphism of GPX1 is associated with the risk of bladder but not prostate cancer: evidence from a meta-analysis.
Men T; Zhang X; Yang J; Shen B; Li X; Chen D; Wang J
Tumour Biol; 2014 Jan; 35(1):269-75. PubMed ID: 23975365
[TBL] [Abstract][Full Text] [Related]
31. The NQO1 Pro187Ser polymorphism and breast cancer susceptibility: evidence from an updated meta-analysis.
Peng Q; Lu Y; Lao X; Chen Z; Li R; Sui J; Qin X; Li S
Diagn Pathol; 2014 May; 9():100. PubMed ID: 24884893
[TBL] [Abstract][Full Text] [Related]
32. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
33. Investigation of NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in prostate cancer.
Ergen HA; Gormus U; Narter F; Zeybek U; Bulgurcuoglu S; Isbir T
Anticancer Res; 2007; 27(6B):4107-10. PubMed ID: 18225579
[TBL] [Abstract][Full Text] [Related]
34. Genetic variants of NQO1 gene increase bladder cancer risk in Indian population and meta-analysis.
Mandal RK; Dubey S; Panda AK; Mittal RD
Tumour Biol; 2014 Jul; 35(7):6415-23. PubMed ID: 24676794
[TBL] [Abstract][Full Text] [Related]
35. Genetic polymorphisms in NQO1 and SOD2: interactions with smoking, schistosoma infection, and bladder cancer risk in Egypt.
Goerlitz D; Amr S; Dash C; Saleh DA; El Daly M; Abdel-Hamid M; El Kafrawy S; Hifnawy T; Ezzat S; Abdel-Aziz MA; Khaled H; Zheng YL; Mikhail N; Loffredo CA
Urol Oncol; 2014 Jan; 32(1):47.e15-20. PubMed ID: 24035474
[TBL] [Abstract][Full Text] [Related]
36. The NAD(P)H: quinine oxidoreductase 1 (NQO1) gene 609 C>T polymorphism is associated with gastric cancer risk: evidence from a case-control study and a meta-analysis.
Hu WG; Hu JJ; Cai W; Zheng MH; Zang L; Wang ZT; Zhu ZG
Asian Pac J Cancer Prev; 2014; 15(5):2363-7. PubMed ID: 24716985
[TBL] [Abstract][Full Text] [Related]
37. Association between VEGF gene promoter polymorphisms and bladder cancer: An updated meta-analysis.
Chen CH; Ho CH; Kuan-Hua Huang S; Shen CH; Wu CC; Wang YH
Cytokine; 2020 Jul; 131():155112. PubMed ID: 32361400
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms in NQO1 and MPO genes and risk for bladder cancer in Tunisian population.
Hemissi I; Ayed H; Naimi Z; Meddeb K; Ayadi M; Zouari S; Zaghbib S; Talbi E; Chebil M; Ouerhani S
Mol Genet Genomic Med; 2021 Nov; 9(11):e1819. PubMed ID: 34549902
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis of the NAD(P)H: quinine oxidoreductase 1 gene 609 C>T polymorphism with esophageal cancer risk.
Wang Z; Hu J; Zhong J
DNA Cell Biol; 2012 Apr; 31(4):560-7. PubMed ID: 22017531
[TBL] [Abstract][Full Text] [Related]
40. Association between NQO1 C609T polymorphism and acute lymphoblastic leukemia risk: evidence from an updated meta-analysis based on 17 case-control studies.
Li C; Zhou Y
J Cancer Res Clin Oncol; 2014 Jun; 140(6):873-81. PubMed ID: 24488035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
